JBiSE  Vol.6 No.8 B , August 2013
Strategies in secondary biliary fibrosis
ABSTRACT
The cellular and molecular mechanisms that mediate hepatic fibrosis have provided a framework of different therapeutic foci to prevent, delay or in such case revert fibrosis and cirrhosis. The fundamental event in development of hepatic fibrosis caused by secondary biliary cholestasis is based on activation of the hepatic stellar cells (HSC) which the primary function is forming fibrosis. The activated HSC cells transform into myofibroblasts with capacity to produce alpha smooth muscle actin (α-SMA). As a result, the HSC activates proliferation of the cholangiocytes and epithelial cells whose functions represent important anti-fibrotic objectives. Some strategies are described as targeting against molecule involved in fibrosis production; and some medications with anti-fibrotic functions that are actually available in the medical arsenal have been tested in experimental animal models and in few clinical studies, and their components act in relation to the fibrotic cascade. In the end, the treatment strategies for hepatic fibrosis can vary on an individual basis depending on the etiology, the risk of fibrosis progression and the predominant pathogenic medium, which indicates that a multi-factorial approach could be necessary. Orthotopic liver transplant continues being the last final alternative for hepatic insufficiency from any cause; however, in no way does it supersede healthy natural liver in survival and adequate function. The investigative arsenal continues to develop rapidly, giving rise to other possible objectives in pre-clinical studies of conceptual trials, such as the utilization of molecular, cellular, drugs therapy and Chinese herbs. Despite being aforementioned, there are no existing ideal alternatives that completely reverse fibrosis in humans. Future usefulness of the majority of management alternatives seems probable and could be feasible.

Cite this paper
Hermosillo-Sandoval, J. , Rodríguez-Carrizález, A. and Miranda-Díaz, A. (2013) Strategies in secondary biliary fibrosis. Journal of Biomedical Science and Engineering, 6, 10-18. doi: 10.4236/jbise.2013.68A2002.
References
[1]   Bataller, R. and Brenner, D.A. (2005) Liver fibrosis. Journal of Clinical Investigation, 115, 209-218.

[2]   Friedman, S.L. (2008) Mechanisms of hepatic fibrogenesis. Gastroenterology, 134, 1655-1669. doi:10.1053/j.gastro.2008.03.003

[3]   Gressner, A.M. and Weiskirchen, R. (2006) Modern pathogenetic concepts of liver fibrosis suggest stellate cells and TGF-beta as major players and therapeutic targets. Journal of Cellular and Molecular Medicine, 10, 76-99. doi:10.1111/j.1582-4934.2006.tb00292.x

[4]   Dranoff, J.A. and Wells, R.G. (2010) Portal fibroblasts: Underappreciated mediators of biliary fibrosis. Hepatology, 51, 1438-1444. doi:10.1002/hep.23405

[5]   Tomur, A., Kanter, M., Gurel, A. and Erboga, M. (2011) The efficiency of CAPE on retardation of hepatic fibrosis in biliary obstructed rats. Journal of Molecular Histology, 42, 451-458. doi:10.1007/s10735-011-9350-6

[6]   Matsuzaki, K., Murata, M., Yoshida, K., Sekimoto, G., Uemura, Y., Sakaida, N., et al. (2007) Chronic inflammation associated with hepatitis C virus infection perturbs hepatic transforming growth factor beta signaling, promoting cirrhosis and hepatocellular carcinoma. Hepatology, 46, 48-57. doi:10.1002/hep.21672

[7]   Miranda-Díaz, A.G., Hermosillo-Sandoval, J.M., LópezGuillén, G.G., Cardona-Munoz, E.G., García-Iglesias, T., Pacheco-Moisés, F., et al. (2010) Tumor necrosis factor and Interleukin-6 levels among patients suffering a bile duct injury during cholecystectomy. Revista Médica de Chile, 138, 1259-1263.

[8]   Miranda-Díaz, A.G., Hermosillo-Sandoval, J.M., Ortiz, G.G., Lizardi-García, D., Cardona-Munoz, E.G., Pacheco-Moisés, F. (2010) Serum oxidative stress is increased in patients with post cholecystectomy bile duct injury. Revista Espanola de Enfermedades Digestivas, 102, 352-356. doi:10.4321/S1130-01082010000600002

[9]   Forbes, S.J. and Parola, M. (2011) Liver fibrogenic cells. Best Practice & Research Clinical Gastroenterology, 25, 207-217. doi:10.1016/j.bpg.2011.02.006

[10]   Kalluri, R. and Neilson, E.G. (2003) Epithelial-mesenchymal transition and its implications for fibrosis. Journal of Clinical Investigation, 112, 1776-1784.

[11]   Larghi, A., Tringali, A., Lecca, P.G., Giordano, M. and Costamagna, G. (2008) Management of hilar biliary strictures. The American Journal of Gastroenterology, 103, 458-473. doi:10.1111/j.1572-0241.2007.01645.x

[12]   Pesce, A., Portale, T.R., Minutolo, V., Scilletta, R., Li Destri, G. and Puleo, S. (2012) Bile duct injury during laparoscopic cholecystectomy without intraoperative cholangiography: A retrospective study on 1100 selected patients. Digestive Surgery, 13, 310-314. doi:10.1159/000341660

[13]   Takeda, K., Kojima, Y., Ikejima, K., Harada, K., Yamashina, S., Okumura, K., et al. (2008) Death receptor 5 mediated-apoptosis contributes to cholestatic liver disease. Proceedings of the National Academy of Sciences of USA, 105, 10895-10900. doi:10.1073/pnas.0802702105

[14]   Tornqvist, B., Zheng, Z., Ye, W., Waage, A., Nilsson, M. (2009) Long-term effects of iatrogenic bile duct injury during cholecystectomy. Clin Gastroenterol Hepatol, 7, 1013-1018. doi:10.1016/j.cgh.2009.05.014

[15]   Tornqvist, B., Stromberg, C., Persson, G. and Nilsson, M. (2012) Effect of intended intraoperative cholangiography and early detection of bile duct injury on survival after cholecystectomy: Population based cohort study. BMJ, 345, Article ID: e6457. doi:10.1136/bmj.e6457

[16]   Hammel, P., Couvelard, A., O’Toole, D., Ratouis, A., Sauvanet, A., Fléjou, J., F., Degott, C., et al. (2001) Regression of liver fibrosis after biliary drainage in patients with chronic pancreatitis and stenosis of the common bile duct. The New England Journal of Medicine, 344, 418-423. doi:10.1056/NEJM200102083440604

[17]   Kisseleva, T. and Brenner, D.A. (2011) Anti-fibrogenic strategies and the regression of fibrosis. Best Practice & Research Clinical Gastroenterology, 25, 305-317. doi:10.1016/j.bpg.2011.02.011

[18]   Tsalis, K.G., Christoforidis, E.C., Dimitriadis, C.A., Kalfadis, S.C., Botsios, D.S. and Dadoukis, J.D. (2003) Management of bile duct injury during and after laparoscopic cholecystectomy. Surgical Endoscopy, 17, 31-37. doi:10.1007/s00464-001-9230-3

[19]   Strasberg, S.M., Hertl, M. and Soper, N.J. (1995) An analysis of the problem of biliary injury during laparoscopic cholecystectomy. Journal of the American College of Surgeons, 180, 101-125.

[20]   Pausawasadi, N., Soontornmanokul, T. and Rerknimitr, R. (2012) Role of fully covered self-expandable metal stent for treatment of benign biliary strictures and bile leaks. Korean Journal of Radiology, 13, S67-S73. doi:10.3348/kjr.2012.13.S1.S67

[21]   Barauskas, G., Paskauskas, S., Dambrauskas, Z., Gulbinas, A. and Pundzius, J. (2012) Referral pattern, management, and long-term results of laparoscopic bile duct injuries: A case series of 44 patients. Medicina, 48, 138-144.

[22]   Smyk, D., Cholongitas, E., Kriese, S., Rigopoulou, E.I. and Bogdanos, D.P. (2011) Primary biliary cirrhosis: Family stories. Autoimmune Diseases, 2011, Article ID: 189585. doi:10.4061/2011/189585

[23]   Smyk, D., Rigopoulou, E.I., Zen, Y., Abeles, R.D., Billinis, C., Pares, A., et al. (2012) Role for mycobacterial infection in pathogenesis of primary biliary cirrhosis? World Journal of Gastroenterology, 18, 4855-4865. doi:10.3748/wjg.v18.i35.4855

[24]   Deng, B.C., Lv, S., Cui, W., Zhao, R., Lu, X., Wu, J. and Liu, P. (2012) Novel ATP8B1 mutation in an adult male with progressive familial intrahepatic cholestasis. World Journal of Gastroenterology, 18, 6504-6509. doi:10.3748/wjg.v18.i44.6504

[25]   Hartley, J.L., Davenport, M. and Kelly, D.A. (2009) Biliary atresia. Lancet, 374, 1704-1713. doi:10.1016/S0140-6736(09)60946-6

[26]   Hsiao, C.H., Chang, M.H., Chen, H.L., Lee, H.C., Wu, T.C., Lin, C.C., et al. (2008) Universal screening for biliary atresia using an infant stool color card in Taiwan. Hepatology, 47, 1233-1240. doi:10.1002/hep.22182

[27]   Basset, M.D. and Murray, K.F. (2008) Biliary atresia. Recent progress. Journal of Clinical Gastroenterology, 42, 720-729. doi:10.1097/MCG.0b013e3181646730

[28]   Muraji, T., Suskind, D.L. and Irie, N. (2009) Biliary atresia: A new immunological insight into etiopathogenesis. Expert Review of Gastroenterology & Hepatology, 3, 599-606. doi:10.1586/egh.09.61

[29]   Allen, S.R., Jafri, M., Donnelly, B., McNeal, M., Witte, D., Bezerra. J. et al. (2007) Effect of rotavirus strains on the murine model of biliary atresia. Journal of Virology, 81, 1671-1679. doi:10.1128/JVI.02094-06

[30]   Rauschenfels, S., Krassmann, M., Al-Masri, A.N., Verhagen, W., Leonhardt, J., Kuebler, J. F., et al. (2009) Incidence of hepatotropic viruses in biliary atresia. European Journal of Pediatrics, 168, 469-476. doi:10.1007/s00431-008-0774-2

[31]   Narayanaswamy, B., Gonde, C., Tredger, J.M., Hussain, M., Vergani, D. and Davenport, M. (2007) Serial circulating markers of inflammation in biliary atresia—Evolution of the post-operative inflammatory process. Hepatology, 46, 180-187. doi:10.1002/hep.21701

[32]   Pakarinen, M.P. and Rintala, R.J. (2011) Surgery of biliary atresia. Scandinavian Journal of Surgery, 100, 49-53.

[33]   Roquete, M.L., Ferreira, A.R., Fagundes, E.D., Castro, L.P., Silva, R.A. and Penna, F.J. (2008) Accuracy of echogenic portal enlargement image on ultrasonographic exams and histopathology in differential diagnosis of biliary atresia. Journal of Pediatrics, 84, 331-336. doi:10.2223/JPED.1811

[34]   Fernandez, M., Mejias, M., Garcia-Pras, E., Mendez, R., Garcia-Pagan, J.C. and Bosch, J. (2007) Reversal of portal hypertension and hyperdynamic splanchnic circulation by combined vascular endothelial growth factor and platelet-derived growth factor blockade in rats. Hepatology, 46, 1208-1217. doi:10.1002/hep.21785

[35]   Yoshiji, H., Kuriyama, S., Yoshii, J., Ikenaka, Y., Noguchi, R., Hicklin, D.J., et al. (2003) Vascular endothelial growth factor and receptor interaction is a prerequisite for murine hepatic fibrogenesis. Gut, 52, 1347-1354. doi:10.1136/gut.52.9.1347

[36]   Kim, M.Y. and Baik, S.K. (2009) Hyperdynamic circulation in patients with liver cirrhosis and portal hypertension. Korean Journal of Gastroenterology, 54, 143-148. doi:10.4166/kjg.2009.54.3.143

[37]   Yoshiji, H., Kuriyama, S., Yoshii, J., Ikenaka, Y., Noguchi, R., Nakatani, T., et al. (2001) Angiotensin-II type 1 receptor interaction is a major regulator for liver fibrosis development in rats. Hepatology, 34, 745-750. doi:10.1053/jhep.2001.28231

[38]   Xing, T., Li, L., Cao, H. and Huang, J. (2007) Altered immune function of monocytes in different stages of patients with acute on chronic liver failure. Clinical & Experimental Immunology, 147, 184-188.

[39]   Ling, H., Roux, E., Hempel, D., Tao, J., Smith, M., Lonning, S., Zuk, A., Arbeeny, C. and Ledbetter, S. (2013) Transforming growth factor β neutralization ameliorates pre-existing hepatic fibrosis and reduces cholangiocarcinoma in thioacetamide-treated rats. PLoS One, 8, Article ID: e54499. doi:10.1371/journal.pone.0054499

[40]   Wang, B., Li, W., Chen, Y., Wang, Y., Sun, C., Chen, Y., Lu, H., Fan, J. and Li, D. (2012) Coexpression of Smad7 and UPA attenuates carbon tetrachloride-induced rat liver fibrosis. Medical Science Monitor, 18, 394-401. doi:10.12659/MSM.883479

[41]   del Pilar, Alatorre-Carranza, M., Miranda-Díaz, A., YanezSánchez, I., Pizano-Martínez, O., Hermosillo-Sandoval, J.M., Vázquez-Del Mercado, M., et al. (2009) Liver fibrosis secondary to bile duct injury: Correlation of Smad7 with TGF-beta and extracellular matrix proteins. BMC Gastroenterology, 9, 81. doi:10.1186/1471-230X-9-81

[42]   Sun, C.K., Chen, C.H., Kao, Y.H., Yuen, C.M., Sheu, J.J., Lee, F.Y., et al. (2011) Bone marrow cells reduce fibrogenesis and enhance regeneration in fibrotic rat liver. Journal of Surgical Research, 169, e15-e26. doi:10.1016/j.jss.2010.03.023

[43]   Takami, T., Terai, S. and Sakaida, I. (2011) Novel findings for the development of drug therapy for various liver diseases: Current state and future prospects for our liver regeneration therapy using autologous bone marrow cells for decompensated liver cirrhosis patients. Journal of Pharmacological Sciences, 115, 274-278. doi:10.1254/jphs.10R13FM

[44]   Yoshiji, H., Noguchi, R., Ikenaka, Y., Namisaki, T., Kitade, M., Kaji, K., et al. (2009) Losartan, an angiotensin-II type 1 receptor blocker, attenuates the liver fibrosis development of non-alcoholic steatohepatitis in the rat. BMC Research Notes, 2, 70. doi:10.1186/1756-0500-2-70

[45]   Ni, S., Li, Y., Huang, S., Luo, W., Li, C. and Li, X. (2012) Perindopril and losartan attenuate intrahepatic toll-like receptor 4 protein expression in rats with bile duct ligation-induced hepatic fibrosis. Nan Fang Yi Ke Da Xue Xue Bao, 32, 211-214.

[46]   Siqueira, O.H., Herani, F.B., de Paula, R.E., Ascoli, F.O., da Nóbrega, A.C., Carvalho A.C., et. al. (2013) Tamoxifen decreases the myofibroblast count in the healing bile duct tissue of pigs. Clinics, 68, 101-106. doi:10.6061/clinics/2013(01)OA16

[47]   He, H., Mennone, A., Boyer, J.L. and Cai, S.Y. (2011) Combination of retinoic acid and ursodeoxycholic acid attenuates liver injury in bile duct-ligated rats and human hepatic cells. Hepatology, 53, 548-557. doi:10.1002/hep.24047

[48]   Mas, N., Tasci, I., Comert, B., Ocal, R. and Mas, M.R. (2008) Ursodeoxycholic acid treatment improves hepatocyte ultrastructure in rat liver fibrosis. World Journal of Gastroenterology, 14, 1108-1111. doi:10.3748/wjg.14.1108

[49]   Chen, Y.H., Lan, T., Li, J., Qiu, C.H., Wu, T., Gou, H.J. and Lu, M.Q. (2012) Gardenia jasminoides attenuates hepatocellular injury and fibrosis in bile duct-ligated rats and human hepatic stellate cells. World Journal of Gastroenterology, 18, 7158-7265. doi:10.3748/wjg.v18.i48.7158

[50]   Ostapowicz, G., Fontana, R.J., Schiodt, F.V., Larson, A., Davern, T.J., Han, S.H., et al. (2002) Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Annals of Internal Medicine, 137, 947-954. doi:10.7326/0003-4819-137-12-200212170-00007

[51]   Lee, W.M. (2012) Recent developments in acute liver failure. Best Practice & Research Clinical Gastroenterology, 26, 3-16. doi:10.1016/j.bpg.2012.01.014

[52]   Services USDoHaH (2005) Annual report of the US organ procurement and transplantation network and the scientific registry of transplant recipients: Transplant data 1995-2004. Health Resources and Services Administration, Healthcare Systems Bureau, Division of Transplantation, Rockville.

 
 
Top